James R. Murray
Corporate Officer/Principal chez University of Bristol
Profil
James R.
Murray was the founder of Hunter-Fleming Ltd.
(1999) where he held the title of Chief Executive Officer and Shire Pharmaceuticals, Inc. (1999) where he held the title of Principal.
Dr. Murray is also the founder of Shire Plc.
Currently, Dr. Murray holds the title of Principal at the University of Bristol.
Dr. Murray's former positions include Chairman at ProXara Biotechnology Ltd.
and Meldex International Plc, Director at Trident Pharmaceuticals, Inc., and Principal at Koninklijke Gist Brocades NV and Astellas Pharma Global Development, Inc.
Postes actifs de James R. Murray
| Sociétés | Poste | Début |
|---|---|---|
| University of Bristol | Corporate Officer/Principal | - |
Anciens postes connus de James R. Murray
| Sociétés | Poste | Fin |
|---|---|---|
| MELDEX INTERNATIONAL PLC | Président | 19/01/2009 |
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Fondateur | 23/05/2008 |
Astellas Pharma Global Development, Inc.
 Astellas Pharma Global Development, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma Global Development, Inc. provides business services. The company is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
Trident Pharmaceuticals, Inc.
 Trident Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Trident Pharmaceuticals, Inc. develops novel biologics for the treatment of autoimmune disorders. The company was founded by Charles M. Cohen and Robin Brown in March 2006 and is headquartered in Boston, MA. | Directeur/Membre du Conseil | - |
Koninklijke Gist Brocades NV
 Koninklijke Gist Brocades NV Pharmaceuticals: OtherHealth Technology Part of DSM-Firmenich AG, Koninklijke Gist Brocades NV is a Dutch company that manufactures and markets biotechnological products. The private company is based in Delft, the Netherlands. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
Trident Pharmaceuticals, Inc.
Trident Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Trident Pharmaceuticals, Inc. develops novel biologics for the treatment of autoimmune disorders. The company was founded by Charles M. Cohen and Robin Brown in March 2006 and is headquartered in Boston, MA. | Health Technology |
Koninklijke Gist Brocades NV
Koninklijke Gist Brocades NV Pharmaceuticals: OtherHealth Technology Part of DSM-Firmenich AG, Koninklijke Gist Brocades NV is a Dutch company that manufactures and markets biotechnological products. The private company is based in Delft, the Netherlands. | Health Technology |
Hunter-Fleming Ltd.
 Hunter-Fleming Ltd. Pharmaceuticals: MajorHealth Technology Hunter-Fleming Ltd. dvelops pharmaceutical products. The company was founded by James R. Murray, John S. Fox and Ernst Wülfert in February 1999 and is headquartered in Brixham, the United Kingdom. | Health Technology |
ProXara Biotechnology Ltd.
 ProXara Biotechnology Ltd. Pharmaceuticals: MajorHealth Technology ProXara Biotechnology Limited is a recently-formed biotechnology company whose mission is to be a world leader in the development of novel therapeutically-relevant cell-based and in-vitro high throughput screens for drug discovery in the oncology field. The Company was founded by Professor Jeremy Tavaré in the Department of Biochemistry at the University of Bristol and was incorporated in March 2001. The company is supported by an experienced and entrepreneurial management team. ProXara has received funding from the Sulis Seedcorn Fund Partnership Limited, Catalyst BioMedica, The Wellcome Trust and private sources. Its premises are currently in the School of Medical Sciences in the University of Bristol. ProXara has established a portfolio of novel cell-based and in-vitro assays against important intra-cellular targets in cancer (primarily breast and prostate) for screening against both internal and customer compound collections. Breast and prostate cancers are the most prevalent malignancies in women and men respectively, and the second highest cause of cancer deaths. The company's technologies will allow the discovery of drugs with a completely novel mode of action against relevant and validated targets. ProXara is currently undertaking optimization of a series of proprietary drug-like molecules which could provide a novel route for the treatment of cancer. | Health Technology |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Meldex International Plc
 Meldex International Plc Miscellaneous Commercial ServicesCommercial Services Meldex International Plc develops medicines and healthcare products using polymer technologies. The firm has strategic alliances with various global pharmaceutical companies, including Barr Pliva and FMC BioPolymer, Inc. It has additional offices in London, Paris, Milan, Vienna, Berlin and Tampa & Kansas City. The company was founded in 1996 and is located in Cambridge, UK | Commercial Services |
Astellas Pharma Global Development, Inc.
Astellas Pharma Global Development, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma Global Development, Inc. provides business services. The company is headquartered in Deerfield, IL. | Health Technology |